Literature DB >> 1125484

Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites.

D J Boullin, D G Grahame-Smith, R P Grimes, H F Woods.   

Abstract

1 Blood platelets from normal human subjects were isolated and aggregated in vitro with adenosine diphosphate (ADP) or 5-hydroxytryptamine (5-HT). 2 The effects of chlorpromazine and 7 major metabolites upon 5-HT-induced aggregation were investigated. 3 All the phenothiazines inhibited 5-HT-induced aggregation when added to platelet rich plasma 3 min prior to 5-HT. 4 There were no qualitative differences in the inhibitory effects, but inhibitory potency varied over a wide range. The decreasing order of potency was monodesmethylchlorpromazine, chlorpromazine, 7-hydroxychlorpromazine, didesmethylchlorpromazine, 3,7 -dimethoxy-chlorpromazine, didesmethylchlorpromazine sulphoxide, chlorpromazine sulphoxide, chlorpromazine nitroxide.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1125484      PMCID： PMC1666266          DOI： 10.1111/j.1476-5381.1975.tb07338.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  19 in total

1.  Diminution of 5-hydroxytryptamine in thrombocytes in vitro by chlorpromazine and related compounds.

Authors:  G BARTHOLINI; A PLETSCHER; K F GEY
Journal:  Experientia       Date:  1961-12-15

2.  Model metabolites of chlorpromazine and promazine: relative activities in some pharmacological and behavioral tests.

Authors:  H S POSNER; E HEARST; W L TAYLOR; G J COSMIDES
Journal:  J Pharmacol Exp Ther       Date:  1962-07       Impact factor: 4.030

3.  Subcellular distribution of some phenothiazines in blood platelets of rabbit.

Authors:  E Solatunituri; L Ahtee
Journal:  J Pharm Pharmacol       Date:  1968-04       Impact factor: 3.765

4.  Effects of 5-hydroxytryptamine on platelet aggregation.

Authors:  H R Baumgartner; G V Born
Journal:  Nature       Date:  1968-04-13       Impact factor: 49.962

5.  Effect of chlorpromazine and reserpine on the blood platelets of rabbit. An electron microscope study.

Authors:  A Telkkä; M Nyholm; M K Paasonen
Journal:  Experientia       Date:  1964-01-15

6.  Effect of chlorpromazine and some of its metabolites on the dopamine-sensitive adenylate cyclase of rat brain striatum.

Authors:  R J Miller; L L Iversen
Journal:  J Pharm Pharmacol       Date:  1974-02       Impact factor: 3.765

7.  5-Hydroxytryptamine release from blood platelets and haemolysis of red blood cells of rabbit induced by phenothiazines and related compounds.

Authors:  L Ahtee
Journal:  Ann Med Exp Biol Fenn       Date:  1966

8.  A comparative pharmacological study of a series of monohydroxylated and methoxylated chlorpromazine derivatives.

Authors:  A A Manian; D H Efron; M E Goldberg
Journal:  Life Sci       Date:  1965-12       Impact factor: 5.037

9.  A COMPARISON OF PLATELET AGGREGATION PRODUCED BY SEVEN COMPOUNDS AND A COMPARISON OF THEIR INHIBITORS.

Authors:  J R O'BRIEN
Journal:  J Clin Pathol       Date:  1964-05       Impact factor: 3.411

10.  The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 .

Authors:  D J Boullin; A R Green; K S Price
Journal:  J Physiol       Date:  1972-03       Impact factor: 5.182
View more
  9 in total

1.  Proceedings Correlation between ultrastructure and histochemistry of mammalian intrafusal muscle fibres.

Authors:  R W Banks; D Barker; D W Harker; M J Stacey
Journal:  J Physiol       Date:  1975-11       Impact factor: 5.182

Review 2.  Antipsychotic-induced venous thromboembolism: a review of the evidence.

Authors:  Staffan Hägg; Olav Spigset
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  The actions of flupenthixol upon 5-hydroxytryptamine-induced aggregation and the uptake of 5-hydroxytryptamine and dopamine by human blood platelets.

Authors:  D J Boullin; R P Grimes; M W Orr
Journal:  Br J Pharmacol       Date:  1975-12       Impact factor: 8.739

4.  Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.

Authors:  D J Boullin; P A Glenton
Journal:  Br J Pharmacol       Date:  1978-04       Impact factor: 8.739

5.  Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-Dopa.

Authors:  D J Heal; A R Green; D J Boullin; D G Grahame-Smith
Journal:  Psychopharmacology (Berl)       Date:  1976-09-29       Impact factor: 4.530

6.  The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.

Authors:  M W Orr; D J Boullin
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

7.  Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.

Authors:  M B Youdim; A Hefez; B Oppenheim
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

8.  Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment.

Authors:  M Schächter; D P Geaney; D G Grahame-Smith; P J Cowen; J M Elliott
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 9.  Human platelet 5-hydroxytryptamine receptors: binding of [3H]-lysergic acid diethylamide (LSD). Effects of chronic neuroleptic and antidepressant drug administration.

Authors:  D G Grahame-Smith; D P Geaney; M Schachter; J M Elliott
Journal:  Experientia       Date:  1988-02-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.